Genmab — Juni 2015
-
Du kan også analysere det på en anden måde. Hvis ikke der kommer et bud vil jeg godt nok blive nervøs for om stoffet er så godt som lovet. Så sagt med andre ord der må simpelthen komme et bud alt andet lige da en virksomhedsprofil med sådan et stof i biotek altid vil blive opslugt alt andet lige. Det interessante vil være hvordan det vil foregå når det kommer. Vi har et par muligheder til at tjene lidt ekstra når buddet "arriver".
-
Shire considers takeover of Swiss biotech group Actelion: Sunday Times
Pharmaceutical company Shire (SHP.L) is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd (ATLN.VX) Europe's biggest biotech firm, Britain's Sunday Times newspaper reported, citing unnamed sources. An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources. Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock's Friday closing price of 132 francs.
Yahoo Finance (finance.yahoo.com)
-
Kommenterede på Genmab og den løbende ansøgning i Børsen Play for lidt siden. Bortset fra det, så er der ikke den omtale i medierne endnu.
-
store
-
Medwatch kommer nok på lidt senere samt analytikerne.
-
Medwatch har været på siden i lørdags Helge -:) http://medwatch.dk/secure/Medicinal___Biotek/article7766609.ece
-
Novod er vores mand
-
Overskriften på Novods rapport "Dara on steroids"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind